2022 World Conference on Lung Cancer (ePosters)-EP08.02-136. Final Analysis of a Phase II Study: Anlotinib Plus Docetaxel in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer

EP08.02-136. Final Analysis of a Phase II Study: Anlotinib Plus Docetaxel in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer

Back to course

Pdf Summary

This study evaluated the efficacy and safety of combining the anti-angiogenic agent anlotinib with docetaxel in advanced non-small cell lung cancer (NSCLC) patients who had previously failed platinum-based chemotherapy. The study, which enrolled 48 patients, showed that anlotinib plus docetaxel demonstrated a high objective response rate (ORR) and improved progression-free survival (PFS) and overall survival (OS) compared to historical results of docetaxel alone. The combination therapy also showed tolerable adverse events (AEs). Notably, patients who experienced hand-foot skin reactions (HFSR) due to anlotinib had longer survival. The final analysis of the study confirmed these findings.<br /><br />The single-arm phase  study included patients with stage IIIB or IV NSCLC who had previously failed platinum-based doublet chemotherapy and had an ECOG performance status of 0-1. The administration consisted of oral anlotinib (12 mg per day taken for 14 days) and intravenous docetaxel (60 mg/m2 on Day 1 of each 21-day cycle). The primary endpoint was ORR, and secondary endpoints included disease control rate (DCR), PFS, OS, and safety.<br /><br />Results showed an ORR of 35.6%, with a DCR of 84.4%. The median duration of response was 5.7 months, and the median PFS was 5.3 months. The median OS was 13.8 months. Subgroup analysis revealed that patients with HFSR had longer OS compared to those without HFSR. Adverse events were mostly grade 1-2, with no grade 4 events observed.<br /><br />In conclusion, the combination of anlotinib and docetaxel showed promising efficacy and manageable safety in advanced NSCLC patients who had failed platinum-based chemotherapy. The results support the use of this combination as a potential treatment option for these patients. Further research is needed to validate and expand upon these findings.

Asset Subtitle

Juan Shen

Meta Tag

Speaker Juan Shen

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Keywords

anlotinib

docetaxel

non-small cell lung cancer

NSCLC

platinum-based chemotherapy

objective response rate

progression-free survival

overall survival

adverse events

treatment option